RVLPQ.US RVL Pharmaceuticals plc

Healthcare Biotechnology USA Stocks
0.0000 USD
Close of Nov 18, 2026
Market cap
USD 1.11K
P/E
-
P/B
0.00x
ROE
-434.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is RVLPQ.US undervalued?

Graham number

The Graham number of RVL Pharmaceuticals plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RVL Pharmaceuticals plc fundamental analysis

No fundamental analysis for RVL Pharmaceuticals plc yet.

RVL Pharmaceuticals plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. …

Full company profile